These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 5648492

  • 1. Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase.
    Bartholini G, Pletscher A.
    J Pharmacol Exp Ther; 1968 May; 161(1):14-20. PubMed ID: 5648492
    [No Abstract] [Full Text] [Related]

  • 2. [Selective increase of C14-catecholamines in the brain due to peripheral inhibition of decarboxylase].
    Bartholini G, Pletscher A, Burkard WP.
    Helv Physiol Pharmacol Acta; 1967 May; 25(2):CR170-2. PubMed ID: 5588156
    [No Abstract] [Full Text] [Related]

  • 3. Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors.
    Watanabe AM, Parks LC, Kopin IJ.
    J Clin Invest; 1971 Jun; 50(6):1322-8. PubMed ID: 5578236
    [Abstract] [Full Text] [Related]

  • 4. Effect of decarboxylase inhibition and neuroleptic drugs on the DOPA level in rat brain.
    Cegrell L, Nordgren L, Rosengren AM.
    Res Commun Chem Pathol Pharmacol; 1970 Jul; 1(4):479-84. PubMed ID: 4400174
    [No Abstract] [Full Text] [Related]

  • 5. Distribution of DOPA-2- 14 C in relation to DOPA-1- 14 C (carboxyl- 14 C-labelled DOPA) in mice before and after inhibition of DOPA-decarboxylase, studied by whole-body autoradiography.
    Tjälve H, Ullberg S.
    Arch Int Pharmacodyn Ther; 1972 Oct; 199(2):376-88. PubMed ID: 4627124
    [No Abstract] [Full Text] [Related]

  • 6. The effect of L-DOPA on brain polysomes and protein synthesis: probable mediation by intracellular dopamine.
    Weiss BF, Roel LE, Munro HN, Wurtman RJ.
    Adv Neurol; 1974 Oct; 5():87-99. PubMed ID: 4155238
    [No Abstract] [Full Text] [Related]

  • 7. Aromatic amino acid decarboxylase inhibitors.
    Porter CC.
    Fed Proc; 1971 Oct; 30(3):871-6. PubMed ID: 5575298
    [No Abstract] [Full Text] [Related]

  • 8. [Progress in the therapy of parkinsonism with L-dopa: inhibition of dopa decarboxylase].
    Nurzia A.
    Clin Ter; 1975 Feb 15; 72(3):289-95. PubMed ID: 1132216
    [No Abstract] [Full Text] [Related]

  • 9. Effects of L-dopa on accumulation and efflux of monoamines in particles of rat brain homogenates.
    Ng LK, Colburn RW, Kopin IJ.
    J Pharmacol Exp Ther; 1972 Nov 15; 183(2):316-25. PubMed ID: 5083548
    [No Abstract] [Full Text] [Related]

  • 10. Comparative investigation of inhibitors of extracerebral dopa decarboxylase in man and rats.
    Kuruma I, Bartholini G, Tissot R, Fletscher A.
    J Pharm Pharmacol; 1972 Apr 15; 24(4):289-94. PubMed ID: 4402836
    [No Abstract] [Full Text] [Related]

  • 11. Inhibition of dopa decarboxylation by RO4-4602, MK 485 and MK 486 in human liver homogenates.
    Vogel WH, Mahoney K, Hare TA.
    Arch Int Pharmacodyn Ther; 1972 Apr 15; 198(1):85-93. PubMed ID: 4538242
    [No Abstract] [Full Text] [Related]

  • 12. Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors.
    Lotti VJ, Porter CC.
    J Pharmacol Exp Ther; 1970 Apr 15; 172(2):406-15. PubMed ID: 5441162
    [No Abstract] [Full Text] [Related]

  • 13. Effects of peripheral aromatic L-amino acids decarboxylase inhibitor on L-(2- 14 C)-3,4-dihydroxyphenylalanine metabolism in man.
    Messiha FS, Hsu TH, Bianchine JR.
    Biochem Pharmacol; 1972 Aug 01; 21(15):2144-7. PubMed ID: 4645885
    [No Abstract] [Full Text] [Related]

  • 14. The fate of C14-dihydroxyphenylalanine (C14-dopa) in the whole mouse.
    Wurtman RJ, Chou C, Rose C.
    J Pharmacol Exp Ther; 1970 Sep 01; 174(3):351-6. PubMed ID: 5456168
    [No Abstract] [Full Text] [Related]

  • 15. Inhibition of DOPA accumulation by rat brain at critical L-DOPA circulating concentrations.
    Horst WD, Bautz G, Renyi E, Spirt N.
    Adv Neurol; 1974 Sep 01; 5():369-73. PubMed ID: 4440584
    [No Abstract] [Full Text] [Related]

  • 16. The role of the adrenergic system in the action of L-DOPA on brain serotonin.
    Algeri S, Cerletti C.
    Adv Biochem Psychopharmacol; 1974 Sep 01; 10():257-9. PubMed ID: 4846542
    [No Abstract] [Full Text] [Related]

  • 17. Selective rise in brain dopamine by inhibition of extracerebral levodopa decarboxylation.
    Pletscher A, Bartholini G.
    Clin Pharmacol Ther; 1971 Sep 01; 12(2):344-52. PubMed ID: 5577483
    [No Abstract] [Full Text] [Related]

  • 18. The role of brain 5-hydroxytryptamine in the central action of L-DOPA.
    Maj J, Pawlowski L, Sarnek J.
    Adv Biochem Psychopharmacol; 1974 Sep 01; 10():253-6. PubMed ID: 4846541
    [No Abstract] [Full Text] [Related]

  • 19. Effect of different dopa decarboxylase inhibitors on the hypotensive response to alpha-methyldopa in rats.
    Henning M.
    Br J Pharmacol; 1968 Sep 01; 34(1):233P-234P. PubMed ID: 5676035
    [No Abstract] [Full Text] [Related]

  • 20. [Action of a decarboxylase inhibitor on endogenous plasmatic DOPA, in man].
    Geissbuhler F, Constantinidis J, Gaillard JM, des Combes NJ, Tissot R.
    Biomedicine; 1974 Jul 01; 21(7):297-8. PubMed ID: 4433662
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.